Blueprint Medicines Corp (BPMC)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Blueprint Medicines Corp (BPMC) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8012920
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Blueprint Medicines Corp (Blueprint) is a biotechnology company that develops drugs for the treatment of cancers. The company discovers selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-285, for treatment resistant gastrointestinal stromal tumors; BLU-554, used in hepatocellular carcinoma; BLU-667, for ret-mutations, fusions, and predicted resistant mutants, rare genetic disease target, immunokinase targets, and others. Blueprint identifies drug targets by sequencing cancers and mining public data with new genome analysis algorithms. It operates through genomic and cancer research institutions located in the US. Blueprint is headquartered in Cambridge, Massachusetts, the US.

Blueprint Medicines Corp (BPMC) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Blueprint Medicines Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Blueprint Medicines Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Blueprint Medicines Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Blueprint Medicines Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Blueprint Medicines Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Blueprint Medicines Corp, Medical Equipment, Deal Details 10
Venture Financing 10
Blueprint Medicines Raises US$25 Million In Series B Venture Financing 10
Blueprint Medicines Raises US$40 Million In Series A Venture Financing 12
Partnerships 14
Thermo Fisher Scientific Enters into Agreement with Blueprint Medicines 14
Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 15
Personal Genome Diagnostics Enters Into Co-Development Agreement With Blueprint Medicines For Novel Kinase Targets 16
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 17
Equity Offering 18
Blueprint Medicines Raises USD230 Million in Public Offering of Shares 18
Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 20
Blueprint Medicines Corp – Key Competitors 22
Blueprint Medicines Corp – Key Employees 23
Blueprint Medicines Corp – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Oct 31, 2017: Blueprint Medicines Reports Third Quarter 2017 Financial Results 25
Aug 02, 2017: Blueprint Medicines Reports Second Quarter 2017 Financial Results 28
May 03, 2017: Blueprint Medicines Reports First Quarter 2017 Financial Results 29
Mar 09, 2017: Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results 31
Nov 10, 2016: Blueprint Medicines Reports Third Quarter 2016 Financial Results 33
Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results 35
May 10, 2016: Blueprint Medicines Reports First Quarter 2016 Financial Results 36
Mar 11, 2016: Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results 38
Corporate Communications 40
Oct 10, 2017: Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations 40
Nov 14, 2016: Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role 41
Sep 06, 2016: Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President 42
Apr 15, 2016: Blueprint Medicines Appoints Lynn Seely, M.D. to Board of Directors 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Blueprint Medicines Corp, Medical Equipment, Key Facts, 2016 2
Blueprint Medicines Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Blueprint Medicines Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Blueprint Medicines Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Blueprint Medicines Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Blueprint Medicines Corp, Deals By Market, 2011 to YTD 2017 8
Blueprint Medicines Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Blueprint Medicines Raises US$25 Million In Series B Venture Financing 10
Blueprint Medicines Raises US$40 Million In Series A Venture Financing 12
Thermo Fisher Scientific Enters into Agreement with Blueprint Medicines 14
Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 15
Personal Genome Diagnostics Enters Into Co-Development Agreement With Blueprint Medicines For Novel Kinase Targets 16
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 17
Blueprint Medicines Raises USD230 Million in Public Offering of Shares 18
Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 20
Blueprint Medicines Corp, Key Competitors 22
Blueprint Medicines Corp, Key Employees 23
Blueprint Medicines Corp, Subsidiaries 24

★海外企業調査レポート[Blueprint Medicines Corp (BPMC)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bioaster:製薬・医療:M&Aディール及び事業提携情報
    Summary Bioaster is a technology research institute that develops technologies and conducts research on infectious diseases and microbiology. The institute offers services in the therapeutic areas of respiratory diseases, diarrhea, AIDS and tuberculosis. It carries out technological research program …
  • ELITechGroup Inc:医療機器:M&Aディール及び事業提携情報
    Summary ELITechGroup Inc (ELITech) is a medical device company that manufactures and distributes in vitro diagnostic equipment and reagents. The company’s products portfolio includes clinical chemistry, cystic fibrosis, hematology, microbiology and molecular diagnostics. Its clinical chemistry produ …
  • Tobira Therapeutics Inc (TBRA)-製薬・医療分野:企業M&A・提携分析
    Summary Tobira Therapeutics Inc (Tobira), formerly Regado Biosciences, Inc, which develops and commercializes therapies for the treatment of to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. Its pipeline products include Cenicriviroc (CVC) and Ev …
  • Indovina Bank Ltd:企業の戦略的SWOT分析
    Indovina Bank Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Cegid Group SA:企業の戦略的SWOT分析
    Cegid Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Anworth Mortgage Asset Corp (ANH):企業の財務・戦略的SWOT分析
    Summary Anworth Mortgage Asset Corp (Anworth) is a financial service provider that provides mortgage real estate investment services. The company invests in mortgage-backed securities on a leveraged basis. It operates through agency credit-backed securities and non-agency credit-backed securities. A …
  • AEI Services LLC-エネルギー分野:企業M&A・提携分析
    Summary AEI Services LLC (AEI), formerly Ashmore Energy International, is an energy utility company that owns, develops and operates power generation assets. The company also carries out the natural gas transportation and distribution businesses in emerging markets. Its power generation portfolio co …
  • Canadian Overseas Petroleum Ltd (XOP):石油・ガス:M&Aディール及び事業提携情報
    Summary Canadian Overseas Petroleum Ltd (COPL), formerly Velo Energy Inc is an oil and gas company that offers exploration and production of crude oil and natural gas properties. The company operates single well unappraised discoveries in mature basins and bringing them into production. Its projects …
  • Famous Brands Limited (Foodservice):企業の戦略・SWOT・財務情報
    Famous Brands Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Famous Brands Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Saladax Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Saladax Biomedical Inc (Saladax) is a medical equipment company that develops diagnostic tests. The company provides products such as My5-FU, MyPaclitaxel, MyImatinib and MyDocetaxel, among others. Its My5-FU measures and helps physicians to optimize a patient’s exposure to 5-fluorouracil, M …
  • International Zeolite Corp
    International Zeolite Corp - Strategy, SWOT and Corporate Finance Report Summary International Zeolite Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Halma Plc (HLMA):医療機器:M&Aディール及び事業提携情報
    Summary Halma Plc (Halma) develops, produces and sells life protection products to enhance personal and public health. The company’s product portfolio comprises fire detection and suppression systems, corrosion monitoring systems, gas detectors, elevator safety products, water treatment systems, aut …
  • Wolters Kluwer N.V. (WKL):企業の財務・戦略的SWOT分析
    Wolters Kluwer N.V. (WKL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Medica Corp:医療機器:M&Aディール及び事業提携情報
    Summary Medica Corp (Medica) is a medical device company that manufactures and markets in-vitro diagnostic blood testing analyzers. The company’s products comprise clinical chemistry analyzers, electrolyte analyzers, blood gas analyzers, and hematology analyzers, and OEM ISE modules. Medica’s produc …
  • IHI Corp (7013):電力:M&Aディール及び事業提携情報
    Summary IHI Corp (IHI) is a heavy machinery manufacturer. It provides technology oriented products and services to customers in the public, private and industrial sectors across the world. The group designs and manufactures a diverse range of products that includes ships and offshore facilities, str …
  • Sembcorp Industries Ltd (U96):電力:M&Aディール及び事業提携情報
    Summary Sembcorp Industries Ltd (Sembcorp) is a diversified energy, water and marine company. It provides solutions across the energy and utilities value chain, with a focus on gas and power, renewables and environment, and merchant and retail sectors. The company carries out production and supply o …
  • Bristow Group Inc:企業の戦略・SWOT・財務分析
    Bristow Group Inc - Strategy, SWOT and Corporate Finance Report Summary Bristow Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • GKN plc:企業の戦略・SWOT・財務情報
    GKN plc - Strategy, SWOT and Corporate Finance Report Summary GKN plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • NCI Building Systems, Inc. (NCS):企業の財務・戦略的SWOT分析
    NCI Building Systems, Inc. (NCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PT Kimia Farma (Persero) Tbk (KAEF):製薬・医療:M&Aディール及び事業提携情報
    Summary PT Kimia Farma (Persero) Tbk (Kimia Farma) manufactures, commercializes and distributes pharmaceutical products. The company provides ethical (prescription), generic and other products. It offers products in various categories including alimentary system, allergy and immune system, system an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆